Introduction {#s1}
============

Hepatocellular carcinoma (HCC) is the most common malignancy with an increasing mortality rate worldwide. So far, surgical resection remains the most effective treatment for HCC patients; however, the prognosis of HCC patients who underwent curative resection remains unsatisfactory because of high recurrence possibility and metastasis incidence (Ji et al., [@B12]; Forner et al., [@B7]; Torre et al., [@B23]). The utility of conventional clinicopathological parameters, including histopathological characteristics, is insufficient for identifying patient subpopulations at high risk of tumor recurrence and metastasis. Therefore, it is urgent to develop new biomarkers for identifying tumor recurrence and metastasis so that post-operative rational adjuvant treatments can be provided timely.

The reasons for the high recurrence/metastasis rate in HCC are complex and multifactorial (Forner and Raoul, [@B8]). Hepatic damage is an important cause of recurrence and metastasis in HCC. In addition to tumor cells, immune and inflammatory cells such as neutrophils, platelets, and lymphocytes also contribute to tumor cell invasion into the peripheral blood, where tumor cells can survive and reseed distant organs (Chaffer and Weinberg, [@B5]; Hanahan and Weinberg, [@B9]; Casadei et al., [@B4]).

HBV infection leads to liver damage, relating to changes of the lipid metabolism. Several studies have shown that lower serum total cholesterol (TC) level correlated with cancer recurrence in HCC patients with hepatic resection, revealing the possibility to predict surgical outcome by preoperative clinical physiological parameters. Poorer surgical outcome in HCC patients with lower preoperative serum TC level might be caused by long-term liver dysfunction and malnutrition, implying the potential role of lipid composition in determination of operative outcomes in HCC patients (Irshad et al., [@B11]; Wang et al., [@B25]; Lee et al., [@B14]; Zhang et al., [@B28]). Recent studies have reported that serum high-density lipoprotein (HDL) is in relation to incident cancers especially breast cancer. These findings imply that HDL might play a major role in tumorigenesis and tumor progression (Lim et al., [@B16]; Li et al., [@B15]; Wang et al., [@B26]). However, an integrated indicator based on serum TC and HDL levels, which might be superior to reflect the correlation between hepatic damage and tumor stages, has not yet been reported in HCC. Moreover, the potential effects of serum TC and HDL levels on HCC recurrence and metastasis have not been elaborated.

In this study, an index based on serum TC and HDL levels, designated as the systemic hepatic-damage index (SHI), has been developed. The prognostic value of the SHI in HCC patients who underwent surgery was evaluated in two independent cohorts. The correlation between the SHI and systemic immune-inflammation index (SII) scores was also explored. We found that the SHI was a potential biomarker for predicting prognosis of HCC patients undergoing resection and that high recurrence rate in patients with low SHI score might be due to increased SII scores from the host.

Materials and methods {#s2}
=====================

Study design
------------

Ethical approval for the use of human subjects was obtained from the Research Ethics Committee of Zhongnan Hospital. From January 2011 to June 2013, we recruited 188 HBV-HCC patients undergoing resection at Zhongnan Hospital as a training cohort. We next recruited a validation cohort of 177 HBV-HCC patients who underwent resection from July 2013 to December 2015 (Table [1](#T1){ref-type="table"}). HCC was defined according to the data of imaging scans and biochemical assays, and diagnosis was confirmed by histopathology according to the criteria of the American Association for the Study of Liver Diseases guidelines. The stage of HCC was determined according to the BCLC guidelines (Bruix and Sherman, [@B2]). Tumor size was defined using the diameter of the single largest lesion. Tumor differentiation was defined using the Edmondson grading system (Wittekind, [@B27]).

###### 

The clinicopathologic characteristics of patients in the training and validation cohorts.

  **Characteristics**                **Training cohort**   **Validation cohort**   ***P***           
  ----------------------- ---------- --------------------- ----------------------- --------- ------- -------
  Age (years)             ≤50        69                    36.70                   68        38.42   0.747
                          \>50       119                   63.30                   109       61.58   
  Sex                     Women      26                    13.83                   32        18.08   0.316
                          Men        162                   86.17                   145       81.92   
  HBsAg                   Negative   22                    11.70                   21        11.86   1.000
                          Positive   166                   88.30                   156       88.14   
  Liver cirrhosis         No         40                    21.28                   43        24.29   0.533
                          Yes        148                   78.72                   134       75.71   
  No. of tumors           Single     151                   80.32                   148       83.62   0.497
                          Multiple   37                    19.68                   29        16.38   
  Tumor size, cm          ≤5         119                   63.30                   107       60.45   0.591
                          \>5        69                    36.70                   70        39.55   
  Tumor encapsulation     Complete   114                   60.64                   121       68.36   0.128
                          None       74                    39.36                   56        31.64   
  Satellite lesion        No         165                   87.77                   161       90.96   0.397
                          Yes        23                    12.23                   16        9.04    
  Vascular invasion       No         118                   62.77                   104       58.76   0.454
                          Yes        70                    37.23                   73        41.24   
  Tumor differentiation   I--II      116                   61.70                   114       64.41   0.664
                          III--IV    72                    38.30                   63        35.59   
  Child-Pugh score        A          177                   94.15                   159       90.87   0.175
                          B          11                    5.85                    18        9.13    
  BCLC stage              0+A        137                   72.87                   139       78.53   0.224
                          B+C        51                    27.13                   38        21.47   
  AFP, ng/mL                         2,391 ± 588           3,328 ± 858             0.360             
  ALT, U/L                           36.27 ± 2.08          38.86 ± 2.01            0.415             
  TB, umol/L                         12.40 ± 0.40          11.80 ± 0.36            0.270             
  Albumin, g/L                       40.24 ± 0.23          40.40 ± 0.26            0.650             
  PT, s                              12.38 ± 0.07          12.46 ± 0.08            0.458             
  TC, mmol/L                         4.10 ± 0.06           4.19 ± 0.07             0.317             
  HDL, mmol/L                        1.25 ± 0.02           1.27 ± 0.03             0.718             
  SHI                                5.23 ± 0.14           5.35 ± 0.16             0.560             

*AFP, α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; TB, total bilirubin; PT, prothrombin time;TC, total cholesterol; HDL, high-density lipoprotein; SHI, systemic hepatic-damage index*.

Follow-up and tumor recurrence
------------------------------

Follow-up for HCC patients ended in July 2016. The time to recurrence (TTR) was defined as the interval between surgery and any diagnosed intrahepatic or extrahepatic recurrence. The overall survival (OS) was defined as the interval between the date of surgery and the date of death, or the interval between surgery and the last observation.

Systemic hepatic-damage index
-----------------------------

The serum TC and HDL concentrations were determined by immunoturbidimetry, using Olympus AU5831 automated biochemistry analyzer. Serum samples were collected 2 days before surgery, and stored at −80°C before detection. The SHI was defined as follows: SHI = TC × HDL. The cutoff value of SHI for predicting tumor recurrence in the training cohort was determined by the X-tile 3.6.1 software (Camp et al., [@B3]). Results from X-Tile analysis revealed an optimal cutoff point for the SHI 2.84 in the training cohort (Supplementary Figure [1](#SM2){ref-type="supplementary-material"}). Thus, patients were stratified into SHI high (\>2.84) or low (≤2.84) groups for all subsequent analyses.

Systemic immune-inflammation index
----------------------------------

The SII was defined as follows: SII = P×N/L, where P, N, and L were the preoperative peripheral platelet, neutrophil, and lymphocyte counts, respectively (Hu et al., [@B10]).

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 16.0 software. Experimental values for continuous variables were expressed as the mean ± standard error of the mean. The chi-squared test, Fisher\'s exact probability tests and the Student\'s *t*-test were used to evaluate the significance of differences in data between groups. If variances within groups were not homogeneous, the non-parametric Mann--Whitney test or the Wilcoxon signed-rank test was used. Kaplan--Meier survival curves and log-rank tests was used to analyze the relationships between serum SHI scores and TTR and OS, and *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Patient characteristics
-----------------------

The clinicopathologic characteristics of HBV-HCC patients are showed in Table [1](#T1){ref-type="table"}. In the training cohort, 89 of 188 HBV-HCC patients undergoing resection suffered recurrence with a median follow-up time of 30.9 months (range 0.3--36.8 months) and 51 of 188 HBV-HCC patients died before the last follow-up (median follow-up 33.0 months, range 3.2--36.8 months). The validation cohort comprised 61 of 177 HBV-HCC patients who confirmed recurrence with a median follow-up time of 20.0 months (range 1.0--30.3 months), and 140 HBV-HCC patients were still alive at a median follow-up of 22.5 months (range 4.0--30.3 months). In the training and validation cohorts, all clinicopathathologic characteristics were similar (Table [1](#T1){ref-type="table"}).

Prognostic value of SHI in the training cohort
----------------------------------------------

Using the X-tile 3.6.1 software, the optimal cutoff value (2.84) was set as to stratify HBV-HCC patients into low SHI (≤2.84) and high (\>2.84) groups (Supplementary Figure [1](#SM2){ref-type="supplementary-material"}). Kaplan-Meier analysis showed that TTR of HBV-HCC patients with low SHI was significantly shorter (*p* \< 0.001, Figure [1A](#F1){ref-type="fig"}) and had higher recurrence rates than those with a high SHI (78.95 vs. 43.79%). Furthermore, the OS of HBV-HCC patients with low SHI was significantly shorter (*p* = 0.047, Figure [1A](#F1){ref-type="fig"}) than those with high SHI (42.11 vs. 25.44%). In multivariate analysis, the SHI was an independent indicator for TTR \[Hazard ratio (HR), 2.97; 95% confidence interval (CI): 1.58--5.58; *p* = 0.001; Table [2](#T2){ref-type="table"}\] and OS (HR, 2.82; 95% CI: 1.25--6.39; *p* = 0.013; Table [2](#T2){ref-type="table"}) of HBV-HCC patients. The area under curve (AUC) was used to assess the discrimination ability of SHI and clinical factors for TTR and OS (Figure [1B](#F1){ref-type="fig"}). The AUC for SHI was 0.56 (95% CI, 0.48--0.65; Sensitivity, 0.169; Specificity, 0.959; Youden\'s index, 0.128) for TTR, and 0.54 (95% CI, 0.44--0.663; Sensitivity, 0.157; Specificity, 0.919; Youden\'s index, 0.076) for OS (Supplementary Table [1](#SM1){ref-type="supplementary-material"}), which was the strongest factor among clinical factors \[tumor size, tumor number, tumor differentiation, tumor encapsulation, vascular invasion, α-fetoprotein (AFP), and Barcelona Clinic Liver Cancer (BCLC) stage\] for predicting tumor recurrence and survival of HBV-HCC patients.

![Prognostic significance of SHI in HCC patients underwent curative resection. Prognostic significance of SHI in HCC patients undergoing resection. The Kaplan--Meier analysis of OS and TTR for SHI in the training **(A)** and validation **(B)** cohorts. Predictive ability of SHI was compared with other clinical parameters by ROC curves in the training **(C)** and validation **(D)** cohorts.](fphys-08-00480-g0001){#F1}

###### 

Multivariate Cox regression analyses in the training and validation cohort.

  **Variables**                                **TTR**                **OS**                              
  -------------------------------------------- ---------------------- ----------- ----------------------- -----------
  **TRAINING COHORT**                                                                                     
  AFP, ng/ml (\>400 vs. ≤400)                  0.832 (0.488--1.416)   0.497       0.390 (0.171--0.892)    **0.026**
  No. of tumors, (multiple vs. single)         0.769 (0.414--1.425)   0.403       0.979 (0.434--2.205)    0.958
  Tumor size, cm (\>5 vs. ≤5)                  0.781 (0.461--1.326)   0.361       1.115 (0.564--2.204)    0.754
  Tumor encapsulation, (none vs. complete)     0.893 (0.568--1.404)   0.623       1.089 (0.597--1.984)    0.781
  Satellite lesion, (yes vs. no)               1.167 (0.569--2.395)   0.673       1.754 (0.692--4.444)    0.236
  Vascular invasion, (yes vs. no)              0.987 (0.598--1.631)   0.961       0.864 (0.448--1.665)    0.662
  Tumor differentiation, (III-IV vs. I-II)     1.072 (0.673--1.706)   0.771       1.416 (0.770--2.605)    0.264
  Child-Pugh score, (A vs. B)                  1.777 (0.783--4.033)   0.169       2.248 (0.848--5.961)    0.103
  BCLC stage, (0+A vs. B+C)                    0.593 (0.323--1.090)   0.092       0.354 (0.147--0.853)    **0.021**
  SHI (\>2.84 vs. ≤2.84)                       2.969 (1.579--5.581)   **0.001**   2.824 (1.248--6.388)    **0.013**
  **VALIDATION COHORT**                                                                                   
  AFP, ng/ml (\>400 vs. ≤400)                  1.610 (0.916--2.831)   0.098       1.429 (0.683--2.989)    0.343
  No. of tumors, (multiple vs. single)         0.883 (0.415--1.875)   0.745       0.820 (0.308--2.186)    0.692
  Tumor size, cm (\>5 vs. ≤5)                  0.951 (0.473--1.915)   0.889       0.873 (0.354--2.154)    0.768
  Tumor encapsulation, (none vs. complete)     0.650 (0.373--1.132)   0.128       2.264 (1.087--4.718)    **0.029**
  Satellite lesion, (yes vs. no)               1.244 (0.551--2.828)   0.599       1.348 (0.478--3.802)    0.572
  Vascular invasion, (yes vs. no)              0.800 (0.434--1.475)   0.475       0.469 (0.206--1.069)    0.072
  Tumor differentiation, (III--IV vs. I--II)   1.051 (0.605--1.825)   0.860       0.812 (0.388--1.696)    0.579
  Child-Pugh score, (A vs. B)                  2.691 (0.551--2.828)   **0.033**   3.831 (1.164--12.602)   **0.027**
  BCLC stage, (0+A vs. B+C)                    1.459 (0.434--1.475)   0.356       2.268 (0.793--6.490)    0.127
  SHI, (\>2.84 vs. ≤2.84)                      3.982 (1.806--8.783)   **0.001**   4.417 (1.690--11.542)   **0.002**

*TTR, Time to recurrence; OS, Overall survival; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; SHI, systemic hepatic-damage index. Bold value represents significant (P \< 0.05)*.

Prognostic value of SHI in the validation cohort
------------------------------------------------

The prognostic value of serum SHI level was further assessed using another independent cohort of 177 HBV-HCC patients. The results were similar to those of the training cohort (Figure [1](#F1){ref-type="fig"}). HBV-HCC patients with low SHI level have shorter TTR (*p* \< 0.001, Figure [1B](#F1){ref-type="fig"}) and OS (*p* = 0.013, Figure [1B](#F1){ref-type="fig"}). Cox regression analyses showed that the serum SHI level was an independent indicator of TTR (HR, 3.98; 95% CI, 1.81--8.78; *p* = 0.001; Table [2](#T2){ref-type="table"}) and OS (HR, 4.42; 95% CI, 1.69--11.54; *p* = 0.002; Table [2](#T2){ref-type="table"}) of HBV-HCC patients. The discrimination ability of SHI was 0.54 (95%CI, 0.45--0.64; Sensitivity, 0.131; Specificity, 0.957 Youden\'s index, 0.088) and 0.56 (95% CI, 0.45--0.67; Sensitivity, 0.162; Specificity, 0.950; Youden\'s index, 0.112) for TTR and OS (Figure [1B](#F1){ref-type="fig"}) respectively, which was higher than other clinical factors.

Correlation between SHI and clinical characteristics
----------------------------------------------------

In the training cohort, there was no significant difference in clinical characteristics, including tumor differentiation and tumor size between the high and low SHI groups. HBV-HCC patients with low SHI were more likely to have vascular invasion (*p* = 0.042, Table [3](#T3){ref-type="table"}) in the validation cohort.

###### 

Correlation between the SHI and clinicopathologic characteristics.

  **Clinical characteristics**   **Training cohort**   **Validation cohort**                                                            
  ------------------------------ --------------------- ----------------------- ----- --------------------------------------- ---- ----- -------------------------------------------
  Age                            ≤ 50                  7                       62    1.000                                   7    61    0.250
                                 \>50                  12                      107                                           6    103   
  Sex                            Female                4                       22    0.307[^a^](#TN1){ref-type="table-fn"}   1    31    0.468[^a^](#TN1){ref-type="table-fn"}
                                 Male                  15                      147                                           12   133   
  AFP, ng/mL                     ≤ 400                 11                      128   0.104                                   7    123   0.110
                                 \>400                 8                       41                                            6    41    
  ALT, U/L                       ≤ 75                  19                      158   0.607[^a^](#TN1){ref-type="table-fn"}   9    90    0.392[^a^](#TN1){ref-type="table-fn"}
                                 \>75                  0                       11                                            4    74    
  HBsAg                          Negative              1                       21    0.704[^a^](#TN1){ref-type="table-fn"}   0    21    0.370[^a^](#TN1){ref-type="table-fn"}
                                 Positive              18                      148                                           13   143   
  Liver cirrhosis                No                    5                       35    0.561                                   2    41    0.737[^a^](#TN1){ref-type="table-fn"}
                                 Yes                   14                      134                                           11   123   
  No. of tumor                   Single                18                      133   0.130[^a^](#TN1){ref-type="table-fn"}   10   138   0.450[^a^](#TN1){ref-type="table-fn"}
                                 Multiple              1                       36                                            3    26    
  Tumor size, cm                 ≤ 5                   9                       110   0.139                                   6    101   0.378
                                 \>5                   10                      59                                            7    63    
  Tumor encapsulation            Complete              9                       105   0.225                                   11   110   0.232[^a^](#TN1){ref-type="table-fn"}
                                 None                  10                      64                                            2    54    
  Satellite lesion               No                    17                      148   1.000[^a^](#TN1){ref-type="table-fn"}   12   149   1.000[^a^](#TN1){ref-type="table-fn"}
                                 Yes                   2                       21                                            1    15    
  Vascular invasion              No                    10                      108   0.453                                   4    100   **0.042**[^a^](#TN1){ref-type="table-fn"}
                                 Yes                   9                       61                                            9    64    
  Tumor differentation           I--II                 11                      105   0.805                                   7    107   0.548
                                 III--IV               8                       64                                            6    57    
  Child-Pugh score               A                     16                      161   0.086[^a^](#TN1){ref-type="table-fn"}   11   148   0.625[^a^](#TN1){ref-type="table-fn"}
                                 B                     3                       8                                             2    16    
  BCLC stage                     0+A                   16                      121   0.289[^a^](#TN1){ref-type="table-fn"}   8    131   0.156
                                 B+C                   3                       48                                            5    33    

*AFP, α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; SLI, systemic hepatic-damage index*.

*Fisher exact test. Bold value represents significant (P \< 0.05)*.

The prognostic significance of SHI for HCC patients with negative AFP and early-stage subgroups
-----------------------------------------------------------------------------------------------

The prognostic value of SHI for conventional low-risk or AFP ≤ 400 ng/mL subgroups was further explored. Our results showed that low SHI level was significantly associated with TTR and OS for the variables as follows: AFP ≤ 400 ng/mL for TTR (*p* \< 0.001, Figure [2A](#F2){ref-type="fig"}), BCLC stages 0+A for TTR (*p* = 0.001, Figure [2B](#F2){ref-type="fig"}), AFP ≤ 400 ng/mL for OS (*p* \< 0.001, Figure [2C](#F2){ref-type="fig"}), BCLC 0+A for OS (*p* = 0.022, Figure [2D](#F2){ref-type="fig"}) in the training cohort.

![Prognostic significance of SHI of HCC patients in the low-risk and AFP ≤ 400 ng/mL subgroups. Kaplan--Meier analysis of TTR of HCC patients with AFP ≤ 400 ng/mL and BCLC 0+A in the training (**A**, left and **B**, left) and validation (**A**, right and **B**, right) cohorts. Kaplan--Meier analysis of OS of HCC patients with AFP ≤ 400 ng/mL and BCLC 0+A in the training (**C**, left and **D**, left) and validation (**C**, right and **D**, right) cohorts.](fphys-08-00480-g0002){#F2}

In the validation cohort, the prognostic value of SHI for TTR and OS in HBV-HCC patients was maintained in the AFP-negative group (*p* = 0.014 and *p* = 0.020, respectively, Figure [2](#F2){ref-type="fig"}) and the BCLC 0+A group (*p* = 0.018 and *p* = 0.009, respectively, Figure [2](#F2){ref-type="fig"}).

Correlation between SHI and SII and its prognostic significance for HCC patients with detectable SII
----------------------------------------------------------------------------------------------------

The correlation between perioperative SHI score and perioperative SII score was further explored. The result showed there is a significant negative correlation between SHI and SII (*r* = −0.274; *p* \< 0.001; Figure [3A](#F3){ref-type="fig"}). The SII scores were significantly higher in HBV-HCC patients with low SHI level compared with those with high SHI level (492.31 ± 88.10 vs. 327.30 ± 16.73; *p* = 0.004; Figure [3B](#F3){ref-type="fig"}).

![Correlation between SHI and SII, and its prognostic significance in HCC patients with detectable CTC. **(A)** Relationship between SHI and SII. **(B)** The SII score of HCC patients in the low and high SHI groups. **(C)** The Kaplan--Meier analysis of TTR for the SHI in patients with detectable SII. **(D)** The Kaplan--Meier analysis of OS for SHI in patients with detectable SII.](fphys-08-00480-g0003){#F3}

In light of the close relationship between SHI and SII, we studied the prognostic significance of SHI in HBV-HCC patients with SII. HBV-HCC patients with SHI ≤ 2.84 had higher recurrence rates (61.11 vs. 29.66%; *p* \< 0.05) and a shorter TTR (median, 10.9 months vs. not reached; *p* = 0.011) compared with HBV-HCC patients with SHI \> 2.84 (Figure [3C](#F3){ref-type="fig"}). Furthermore, we also found that overall survival time was significantly lower in HBV-HCC patients with SHI ≤ 2.84 than those with SHI \> 2.84 (*p* = 0.008, Figure [3D](#F3){ref-type="fig"}).

Discussion {#s4}
==========

The blood lipid level, including triglycerides, TC, HDL, low density lipoprotein, and very low density lipoprotein, were reported to have negative correlation with the severity of liver damage in patients with HBV- or HCV-related chronic liver disease. Moreover, low TC level was reported to be in close association with severe liver fibrosis in these patients. It is implied that liver functional reserve became poorer with the decrease of TC (Vere et al., [@B24]; Wang et al., [@B25]). Several studies have shown low serum TC level and low serum HDL level were associated with worse disease-free survival and overall survival in HCC patients undergoing surgical hepatectomy, breast cancer patients, colorectal cancer patients receiving adjuvant chemotherapy, and non-small-cell lung patients with EGFR mutations (Lee et al., [@B14]; Li et al., [@B15]; Wang et al., [@B26]; Zhang et al., [@B28]). However, these studies focused on the prognostic significance of single index of TC or HDL in post-surgery patients with cancers. Combined with TC and HDL in the prognosis of HCC patient has been not reported.

In the present study, a hepatic-damage--based prognostic score was constructed based on TC and HDL levels, and was an independent factor for predicting recurrence rates and survival time of HCC patients after surgery in the training cohort. Furthermore, we collected another independent cohort of HCC patients to validate the clinical value of SHI levels, and found that the clinicopathalogic characteristics of two cohorts were similar, illustrating the reliability and universality of our finding results. Meanwhile, the measurement of SHI is based on standard laboratory measurements of TC and HDL level, which are routinely performed in the clinical setting. Thus, it is a potential of SHI to be used as a marker for tumor recurrence and treatment responsiveness surveillance, which might provide a powerful test enabling accurate and early decision making to tailor the most effective therapy according to characteristics of individual tumors.

In clinical practice, it is difficult to predict tumor relapse in HCC patients with low recurrence risk. Our study demonstrated that preoperative SHI scores retain their prognostic significance in HCC patients with low recurrence risk whom conventional clinical characteristics offer limited information on predicting tumor recurrence and survival. So far, AFP has been the most extensively useful biomarker for diagnosis and treatment evolution of HCC patients (Sato et al., [@B20]; Johnson, [@B13]; Poté et al., [@B19]). However, it is challenging to monitor tumor recurrence and metastasis in 30--40% of low AFP levels patients with HCC (Johnson, [@B13]; Forner et al., [@B7]). Here, we have also shown that detection of the preoperative SHI level is a convenient and good tool for predicting recurrence in low AFP levels patients with HCC. The prognosis predictive value of SHI level in low recurrence risk subgroups would be that clinicians could easily identify HCC patients at high risk of tumor recurrence and metastasis, and provide targeted rational adjuvant therapy after surgery. To date, detection of SHI level has been served as a routine clinical liver function test with commercially available kits. Determination of SHI can be standardized easily to provide accuracy and reproducibility, strengthening its practical significance for determining the most effective therapy for each HCC patient at an early stage.

Recent evidence suggests that chronic immuno-inflammatory cells involve in tumorigenesis and tumor progression (Baecklund et al., [@B1]; Smedby et al., [@B21]; Lim et al., [@B16]). Reducing serum HDL concentration leads to chronic inflammation because of its anti-inflammatory properties. Thus, low HDL level may predict the changes of systemic inflammation and the risk of inflammation-induced tumor. Furthermore, high HDL may protect against tumor, which modulates inflammatory responses with suppressing chemotactic activity of lymphocytes and monocytes and inhibiting cytokine-induced expression of endothelial cell adhesion molecules, and protecting the integrity of lymphocytes from oxidative damage (Cockerill et al., [@B6]; Nofer et al., [@B17]; Tietge et al., [@B22]; Papageorgiou et al., [@B18]). All of those might suggest SHI affect tumor progression through modulating inflammatory responses. When analyzing only the patients with detectable SII, patients with low SHI level had a higher recurrence rate and a shorter TTR than patients with high SHI level. This suggests that SHI are unable to influence tumor cells without assistance from immune and inflammatory cells. In addition, we also found that decreased SHI was associated with vascular invasion, indicating a more aggressive phenotype. Release of tumor cells into circulation is a multiple-step procedure, which includes a great number of ingredients, and SHI acts as one of the major molecules in this procedure (Hu et al., [@B10]). Hence, based on our data, we believe that SHI is a significant negative regulator of SII (*p* \< 0.001), though the correlation was relatively weak (*r* = −0.274). Taken together, these findings indicated that the SHI might increase the SII level by preventing tumor formation, affecting tumor cell survival in the circulation, leading to higher recurrence rates and poor outcomes in HCC patients with low serum SHI levels. Thus, improving the SHI level in HCC patients might be a promising therapeutic strategy to limit tumor recurrence and metastasis in HCC patients after surgery.

Our data shows that SHI can independently predict TTR and OS for HCC patients with resection. Furthermore, continuous monitoring of SHI in peripheral blood of HCC patients might provide available information for managing and facilitating treatment of HCC patients. The role of SHI in increasing SII scores can probably serve as the reason of high recurrence rate and poor prognosis of HCC patients with low SHI level. The cheap and easy detection of SHI level makes SHI serve as a convenient biomarker for predicting prognosis value of HCC individual in future clinical practice. Moreover, improving SHI level in peripheral blood of HCC patients might be a promising therapeutic strategy to reduce the possibility of recurrence and metastasis of HCC patients with resection. However, our study still exist several limitation. In the study, some recognized factors, such as tumor number, tumor size, and tumor differentiation are not independent risk factors for TTR and OS for HCC patients. It might be the reason of short follow-up time and small size of the cohort relatively. Moreover, it should also be noted that there is a hepatitis B virus-positive background in most HCC patients in China. Therefore, a large-cohort, multicenter, long-term study including HCC patients from different background and country is needed to validate the prognostic value of SHI, and this is currently conducted in our center. Furthermore, a comprehensive study of the mechanisms of between SHI and HCC cells also needs to be explored.
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The area under curve for TTR and OS in the training and validation cohort. TTR, Time to recurrence; OS, Overall survival; AUC, the area under curve; CI, confidence interval; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; SHI, systemic hepatic-damage index.
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The optimal cutoff value of SHI was selected by X-tile 3.6.1 software. SHI, systemic hepatic-damage index.

###### 

Click here for additional data file.

HCC

:   Hepatocellular carcinoma

TTR

:   time to recurrence

OS

:   Overall survival

AFP

:   α-fetoprotein

BCLC

:   Barcelona Clinic Liver Cancer

SHI

:   systemic hepatic-damage index

SII

:   systemic immune-inflammation index.
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